Omeros.com

Site Inspections

Overview & More informations

Omeros Corporation, or simply "Omeros," is a privately held biopharmaceutical company that researches, develops, and commercializes small molecule and antibody therapeutics for the treatment of ophthalmic, cardiovascular, and autoimmune diseases. The company is headquartered in Seattle, Washington, and was founded in 1998.

Omeros's lead product, Ocriplasmin, is a recombinant human plasmin approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic vitreomacular adhesion (VMA). VMA is a common eye condition that can cause blurred vision, floaters, and other visual disturbances. Ocriplasmin is administered as a single intravitreal injection and works by dissolving the vitreous, a gel-like substance that fills the eye.

In addition to Ocriplasmin, Omeros is also developing a number of other therapeutic candidates for the treatment of ophthalmic, cardiovascular, and autoimmune diseases. These candidates include:

* OMS721, a small molecule inhibitor of the complement factor 5a receptor (C5aR) for the treatment of dry age-related macular degeneration (AMD)
* OMS906, a small molecule inhibitor of the complement factor D for the treatment of wet AMD
* OMS302, a monoclonal antibody that targets the integrin alpha4beta1 for the treatment of inflammatory bowel disease (IBD)

Omeros is a clinical-stage biopharmaceutical company with a pipeline of promising therapeutic candidates. The company's lead product, Ocriplasmin, is approved for the treatment of VMA, and the company is also developing a number of other therapeutic candidates for the treatment of ophthalmic, cardiovascular, and autoimmune diseases. Omeros is a well-funded company with a strong track record of success, and the company is well-positioned to continue to develop and commercialize innovative new therapies for patients with serious diseases.

Domains Expiration Date Updated